Connect with us

Technology

ixlayer and Ipsos’ “ixInsights 2025” Study Reveals Consumer Expectations for Digital Health and Pharma’s Role in Enhancing Patient Experience

Published

on

Study Captures Drivers and Deterrents to Digital Health to Inform Biopharma Cx, Commercialization and Marketing Efforts

SAN FRANCISCO, April 1, 2025 /PRNewswire/ — ixlayer, a leading cloud-based healthtech platform, with Ipsos, a global leader in market research, have released findings from the inaugural research report, “ixlayer ixInsights 2025: Pharma’s Role in Improving the Health Experience.” The study looks at patients with specific conditions–asthma, COPD, type 2 diabetes, heart disease, psoriasis, or atopic dermatitis–to identify their experiences, motivations and barriers to digital health adoption. More importantly, it looks ahead outlining actionable insight and drivers to enhance biopharma’s customer experience (Cx), commercialization and marketing efforts.

To view the complete “ixlayer ixInsights 2025” study by Ipsos, email contact@ixlayer.com to request a copy.

A resounding 74% of surveyed patients would value help from a pharmaceutical company to reduce their healthcare barriers. These findings explore the health solutions these patients are looking for and the positive impact on the perception of the pharma companies that offer them.

In fact, 8 in 10 patients in this survey said that pharmaceutical companies should provide resources to help them get the care and medicines they need (81%). The report highlights consumers’ strong demand for various digital health solutions from pharma including patient assistance, affordability, easier access to lab testing, tools to help access medication and telehealth services. Consumer sentiment aligns with the 83% of U.S. physicians across specialties that believe at-home diagnostic tests help move patients through the care continuum faster, leading to earlier diagnosis and treatment to support better health, according to a separate 2024 survey of U.S. physicians.

“The expansion of DTC initiatives and services leveraging digital technology for pharma is a hot topic among the biopharma leaders we meet with, and partnering with Ipsos allowed us to uncover the real challenges and opportunities shaping the future of this emerging model,” explained Pouria Sanae, co-founder and CEO, ixlayer. “This survey confirms that patients don’t just want treatment from pharma—they want seamless, digital-first healthcare experiences that fit into their lives.”

“It is crucial for all stakeholders to focus on integrating and developing tools that put patients at the core,” explained Chareen Lim, SVP of Ipsos Healthcare. “The journey towards a seamless patient experience is ongoing, and this study shows there are ample opportunities to innovate and improve within this young and dynamic sector.”

Excerpted data: “ixlayer ixInsights 2025: Pharma’s Role in Improving the Health Experience”

Current adoption is strong, with room for technical improvementsMore than 3 out of 4 respondents agree that digital health solutions have helped maintain better communication with their healthcare providers (77%)They believe that it’s a cost effective way to maintain their health (73%)27% report having technical difficulties when using digital health solutions50% have to use multiple digital health platformsTop digital health solutions 92% of surveyed patients use or have used patient portals for accessing healthcare information and resources82% use or have used telehealth platforms for virtual consultations67% use or have used pharmacy delivery services65% use or have used wearable devices for health62% use or have used at-home diagnostic testing kitsThese patients want pharma to do more 81% of respondents believe pharmaceutical companies should provide resources to help them access care and medicationsOnly 16% strongly believes pharma prioritizes their needsAttributes of digital health services poised to drive usageAbility to consult with healthcare professionals virtually or schedule in person83% of respondents report a likelihood to useAccept insurance coverage for services83% report a likelihood to useSecure options for sharing your health data (e.g., lab test results) with others including your healthcare provider79% report a likelihood to useEasier access for lab testing, at-home kits, or scheduling at service center78% report a likelihood to useProvides digital pharmacy options (e.g., online ordering, prescription delivery)74% report a likelihood to use92% of surveyed patients say their perception of pharma would improve if they offered at least one of the following digital health solutions, including:Ability to consult with healthcare professionals virtually or schedule in person78% say it would improve their perception of pharmaAccept insurance coverage for services83% say it would improve their perception of pharmaSecure options for sharing your health data (e.g., lab test results) with others including your healthcare provider77% say it would improve their perception of pharmaEasier access for lab testing, at-home kits, or scheduling at service center78% say it would improve their perception of pharmaProvides digital pharmacy options (e.g., online ordering, prescription delivery)74% say it would improve their perception of pharma

The study captures consumer sentiment for what’s working and what’s not in digital health. Their top reasons for satisfaction with digital health are: convenience, improved communication with healthcare providers, quicker access to treatment or care, and easier access to the medications they need. The top reasons for dissatisfaction with digital health are: the need to use multiple platforms to get what they need, technical issues, and concerns about data security.

The rise of digital health, telemedicine, and direct-to-patient platforms highlights the growing demand for technology-driven healthcare solutions. As consumers increasingly expect these innovations, the survey findings signal a critical opportunity for pharma to strengthen its relationship with patients. Companies that prioritize patient-centric, digital solutions will be well-positioned to lead in the evolving healthcare ecosystem.

About ixlayer

ixlayer [pronounced: I-X-layer] is the leading provider of cloud-based platforms that power a seamless, end-to-end direct-to-patient healthcare experience. The name reflects our core strength: “i” for robust data and technology infrastructure and “x” for exceptional user experience. ixEngage by ixlayer seamlessly integrates with all healthcare ecosystem partners, connecting biopharma with patients in a user-centric way. This proprietary technology accelerates the path to diagnoses, supports optimal care, drives operational efficiency, and improves health equity and outcomes for all. To date, ixlayer has activated over four million patient care journeys, simplifying the complex web of healthcare. Learn more at www.ixlayer.com.

About Ipsos

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

Our tagline “Game Changers” sums up our ambition to help our 5,000 customers move confidently through a rapidly changing world.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD). ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com

Survey Methodology
These are some of the findings of an ixlayer patient survey, with data collection done by Ipsos. A total of n=414 individuals, ages 21+, with at least one of the following conditions was surveyed online between January 6-24, 2025: asthma, COPD, type 2 diabetes, heart disease, psoriasis, or atopic dermatitis. Some quotas were placed around respondent age in order to achieve a nearly even split of baby boomer, Gen X, and millennial respondents. No weights were applied to the data, and the findings reflect the opinion of these survey respondents only. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ixlayer-and-ipsos-ixinsights-2025-study-reveals-consumer-expectations-for-digital-health-and-pharmas-role-in-enhancing-patient-experience-302416443.html

SOURCE ixlayer

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AEWIN Empowers AI-Powered Cybersecurity with Rack-Scale Intel-Based AI Servers and Network Appliances

Published

on

By

TAIPEI, June 3, 2026 /PRNewswire/ — AEWIN Technologies’ high-performance AI servers and network appliances have been widely deployed by leading cybersecurity providers worldwide to accelerate AI-powered applications. This proven hardware portfolio includes high-availability NVMe servers, general-purpose servers, and scalable network appliances tailored for smart cybersecurity and Edge AI.

AEWIN Technologies participates in the BenQ Group Computex AI NOW exhibition and exhibits smart cybersecurity solutions on the 4th floor of Hall 1, Taipei Nangang Exhibition Center from June 2 to June 5. The booth number is M0104, and the BenQ Group companies will together create a smarter and more sustainable future.

The growing adoption of the Internet of Things (IoT) and AI technologies, including LLMs, GenAI, and agentic AI, requires sophisticated network infrastructures capable of handling tremendous amounts of data. For real-world deployments, network security is one of the challenges. Enterprises urgently need smarter and more efficient security solutions to deal with the new threats of cyberattacks.

MIS-5131-2U2 is an NVMe HA Server, Taiwan Excellence Award Winner. Powered by a single Intel Xeon 6700/6500-series processor with P-cores (R1S), it features 24x dual-port NVMe SSDs, high speed NTB communication, and built-in BMC real-time monitoring and automatic responses to heartbeat failures for mission-critical applications. Each node includes three PCIe 5.0 slots for high-throughput NICs, Intel QAT acceleration cards, and GPU/FPGA expansion to support AI workloads.

Powered by dual Intel Xeon 6 processors, BIS-5231 features up to eight PCIe Gen5 expansion slots and twelve storage drive bays with SAS/SATA or NVMe options to meet diverse deployment requirements. Additionally, there are four RJ45 10GbE ports powered by Intel E610 Ethernet controllers to offer high-speed transmission for modern computing demands across Storage, Edge AI, and Networking.

AEWIN also showcases edge servers and network appliances powered by a wide range of Intel processors, from Bartlett Lake-S to Intel Xeon 6 for scalable rack-scale infrastructure supporting high-bandwidth, low-latency, and secure AI infrastructure deployments. They include 2U Edge Computing Servers with the support of dual-width GPU cards and 1U network appliances supporting up to four NICs for advanced infrastructure for AI-powered cybersecurity.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aewin-empowers-ai-powered-cybersecurity-with-rack-scale-intel-based-ai-servers-and-network-appliances-302789824.html

SOURCE AEWIN Technologies

Continue Reading

Technology

Autoliv Strengthens Global Safety Innovation

Published

on

By

VÅRGÅRDA, Sweden, June 3, 2026 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, is taking a significant step to accelerate the development of life-saving mobility solutions through the Autoliv Innovation Center – a new global platform designed to speed up innovation, collaboration, and development of advanced safety technologies. The Autoliv Innovation Center is inaugurated today in Vårgårda, Sweden, the city where Autoliv’s history began.

The Innovation Center builds on more than 70 years of safety expertise rooted in Sweden, where Autoliv’s operations have played a pivotal role in advancing traffic safety on a global scale. Technologies developed here have been scaled worldwide and are today protecting road users across vehicle segments.

With the Autoliv Innovation Center, Autoliv now takes the next step. By bringing research, system architecture, testing, prototyping and pilot production together in one environment, the center enables faster technical evaluation and shorter development cycles. Advanced digital tools are combined with physical labs and test environments to verify performance in realistic and measurable scenarios.

A key foundation of the Innovation Center is Autoliv’s long-standing triple-helix approach, where industry, academia, and society collaborate to address complex safety challenges. The ambition is to create an arena for global cooperation that drives innovation across mobility and society, with the ultimate goal of Saving More Lives.

“The Autoliv Innovation Center is a strategic development in how we advance safety going forward. By bringing the full innovation chain together, we can move faster from insight to real-world impact and scale solutions globally. It is also the natural evolution of our long-established operations in Vårgårda, building on decades of experience and capability. Sweden has played an important role in advancing traffic safety worldwide, and Vårgårda has been central to these accomplishments. What we are doing today is building on that heritage to accelerate the next generation of global safety innovation,” said Fabien Dumont, Executive Vice President & Chief Technology Officer, Autoliv.

Over time, the operation in Vårgårda has been central to innovations for road safety including advanced motorcycle safety solutions, the development of Human Body Models (HBM) that improve injury assessment, Load Limit Management (LLM) technologies that enhance restraint performance, Pyrotechnic Safety Switch (PSS) solutions for electrical safety, and safety systems tailored for commercial vehicles.

Autoliv’s safety solutions save approximately 40,000 lives and reduce around 600,000 injuries every year, a tangible demonstration of how innovation makes a real difference for society. With increased investment and an expanded platform for collaboration, the Autoliv Innovation Center is set to further accelerate the development of next-generation safety solutions and help save even more lives in the future.

Inquiries:
Media: media@autoliv.com
Gabriella Etemad, Tel +46 70 612 64 24, Emelie Ericson, Tel +46 70 957 81 35
Investors & Analysts: ir@autoliv.com
Anders Trapp, Tel +46 709 578 171, Henrik Kaar, Tel +46 709 578 114

About Autoliv

Autoliv, Inc. (NYSE: ALV) (NASDAQ STOCKHOLM: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world, as well as mobility safety solutions, such as commercial vehicles and electrical safety solutions. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2025, our products saved approximately 40,000 lives and reduced around 600,000 injuries.

We have operations in 25 countries, and we drive innovation, research, and development at our 13 technical centers. Our 64,000 employees are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. Sales in 2025 amounted to $10.8 billion. For more information go to www.autoliv.com.

Safe Harbor Statement

This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/autoliv/r/autoliv-strengthens-global-safety-innovation,c4356044

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/autoliv-strengthens-global-safety-innovation-302789827.html

SOURCE Autoliv

Continue Reading

Technology

Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project

Published

on

By

PARIS and SEOUL, South Korea, June 3, 2026 /PRNewswire/ —  Air Liquide has signed a major long-term contract with SK hynix, a global leader in memory semiconductors. The Group will bring its pioneering solutions to SK hynix’s massive industrial project dedicated to advanced packaging of HBM (High-Bandwidth Memory), the backbone of the global AI revolution. The investment of nearly 200 million euros is a first success following the acquisition of DIG Airgas earlier this year, significantly strengthening its leadership in both the region and the Electronics industry.

In order to supply SK hynix’s new packaging and testing fab “P&T7”, located in Cheongju, in the Chungcheongbuk province, Air Liquide will build and operate a state-of-the-art nitrogen production unit. Set to begin operations in late 2027, the facility will supply high-purity gases and high-purity compressed air to the fab in charge of the advanced packaging of HBM chips, a key component of AI development.

This contract demonstrates the immediate value creation by integrating South Korea’s leading industrial gas provider DIG Airgas into Air Liquide. By combining the Group’s world-class proprietary technologies for ultra-high purity carrier gases with DIG Airgas’s extensive local footprint and deep-rooted customer relationships, Air Liquide has significantly accelerated its growth trajectory and potential in the region. This strategic synergy uniquely positions the Group to lead the rapid evolution of AI-driven semiconductor manufacturing. With this new project, the Group will also significantly expand its footprint in the Cheongju industrial basin, where its teams already operate several plants supporting SK hynix, reinforcing its long-term competitive edge in the South Korean market.

Ronnie Chalmers, Air Liquide Group Vice President, in charge of supervising Asia-Pacific, stated: “This milestone partnership reflects our strong confidence in the South Korean economy and our long-standing commitment to being a preferred partner in the global semiconductor supply chain. Thanks to the integration of DIG Airgas, which brought us a secured portfolio of nearly 20 projects, our teams now combine local agility and global innovation to accelerate Air Liquide’s growth. We are proud to support the ambitions of our partner SK hynix as they play a leading role in the AI revolution.”

Air Liquide in South Korea

Since 1996, Air Liquide has been a key player in South Korea, serving major industries, the home healthcare sector, and the development of the hydrogen economy. Through strategic investments such as its advanced molybdenum manufacturing plant and state-of-the-art rare gases purification unit, Air Liquide is a long-term partner providing innovative and sustainable solutions to the semiconductor industry. Following the landmark acquisition of DIG Airgas in January 2026, Air Liquide has significantly expanded its local infrastructure and expertise. With a dedicated team of 1,200 employees in South Korea, the Group is ideally positioned to meet the growing demand for high-tech manufacturing, healthcare, clean energy and mobility across the country’s largest industrial basins.

 

CONTACTS

Corporate Communications

media@airliquide.com

Investor Relations

IRTeam@airliquide.com

 

Oxygen, nitrogen, hydrogen, and many other essential small molecules are the invisible pillars of our world and our lives. They have been at the core of the Group’s activities since its creation in 1902.

A world leader in gases, technologies and services for industry and healthcare, Air Liquide acts as the backbone of numerous economic sectors, serving 4.3 million customers and patients across 59 countries with approximately 65,000 employees. With revenues close to 27 billion euros in 2025, Air Liquide combines strong performance and useful growth.

The Group is a leader with a diversified, resilient business model and a strong local footprint across the globe. Through deep engineering expertise and technological innovation, Air Liquide provides scalable solutions that enhance industrial efficiency, accelerate decarbonization, and strengthen value chains. Strategically exposed to growth markets and megatrends, the Group accompanies major industrial and societal transformations to create long term added value and build a sustainable future.

Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, CAC 40 ESG, EURO STOXX 50, FTSE4Good, and Dow Jones Best-in-Class Europe Index indexes.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/air-liquide-announces-milestone-investment-in-south-korea-to-support-sk-hynixs-advanced-ai-memory-chip-project-302788744.html

SOURCE Air Liquide

Continue Reading

Trending